Emmaus Life Sciences Names LaVoieHealthScience as Strategic Communications Agency of Record

Boston, MA & Torrance, California –

November 7, 2018 – LaVoieHealthScience (LHS), an integrated investor and public relations agency focused on advancing health and science innovations, today announced that it has added Emmaus Life Sciences, Inc. (Emmaus) to its client roster. LHS provides strategic communications programming to Emmaus, helping to ensure all stakeholders – including patients, healthcare practitioners, investors, and other audiences – are educated and aware of sickle cell disease and Emmaus’ dedication to patients with this orphan disease.

Emmaus has a history rooted in scientific discovery. Endari™ (L-glutamine oral powder), approved in July 2017, was developed by Emmaus’ Chairman and CEO Yutaka Niihara, M.D., MPH. Dr. Niihara began researching the benefits of L-glutamine more than 25 years ago in 1992, as a physician treating sickle cell patients at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. Today, the company’s product pipeline includes the potential use of L-glutamine to treat diverticulosis, a GI condition affecting millions, as well as diabetes. In addition, Emmaus is researching cell-sheet technology for treatment of limbal stem-cell deficiency, an orphan disease.

“We understand the importance of extending our visibility and building patient awareness of the treatment options for this debilitating orphan disease,” commented Kurt Kruger, CFO of Emmaus Life Sciences. “LHS, with its focus and expertise in the health and life science industry and connections with influencers, investment community and media make it the right partner for Emmaus.”

“We are honored to be working with Emmaus, a company led by Dr. Niihara that is truly passionate about patients and committed to medical innovation,” said Donna L. LaVoie, President & CEO of LaVoieHealthScience. “We are aligned with Emmaus’ passion to help patients afflicted with sickle cell disease and to raise the visibility of this disease, and the company’s important contributions to this underserved patient community.”

About Endari™ (L-glutamine oral powder)

Indication
Endari is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older.

Important Safety Information
The most common adverse reactions (incidence >10 percent) in clinical studies were constipation, nausea, headache, abdominal pain, cough, pain in extremities, back pain, and chest pain.

Adverse reactions leading to treatment discontinuation included one case each of hypersplenism, abdominal pain, dyspepsia, burning sensation, and hot flash.

The safety and efficacy of Endari in pediatric patients with sickle cell disease younger than five years of age has not been established.

For more information, please see full Prescribing Information of Endari at: www.ENDARIrx.com/PI.

About LaVoieHealthScience

LaVoieHealthScience provides public relations, investor relations, marketing, and digital communications to build recognition and value for health science innovators. The agency has received more than 30 awards during the past seven years in recognition of the work it has done for its industry-leading clients and was recently inducted into the 2018 Inc. 5000 Hall of Fame list of Fastest Growing Private Companies. LaVoieHealthScience represents public and privately-held leaders such as BIO, Carmell Therapeutics, Emmaus Life Sciences, Landos Biopharma, LEO Science & Tech Hub, Life Sciences Corridor, NewLink Genetics, Newron Pharmaceuticals, Origenis GmbH, PathMaker Neurosystems, Scioto Biosciences, SIRION Biotech, Symbiotix Biotherapies, Triumvira Immunologics, XenoTherapeutics, Xontogeny LLC, and other emerging health and science companies. For more information, please visit: https://lavoiehealthscience.com/

###

Media Contact:
Katie Gallagher
Account Manager, PR and Marketing
kgallagher@lavoiehealthscience.com    
617-374-8800 x109

 

7 Podcasts You Should Be Listening To

7 Podcasts You Should Be Listening To

Ever hear of Serial? How about Planet Money? Thanks to the growing popularity of podcasts, programs like these have become household names for millennials and older generations alike. Podcasts have changed the way many of us get our news, listen to stories, and learn about current trends.  They’re convenient, entertaining, informative and industry specific. We’ve put together our top recommendations for keeping up with important biotech and marketing topics; whether you’re a faithful subscriber or a first-time listener, you won’t want to miss these shows!

For your biotech and life science interests…

Our first choice is STAT’s weekly podcast, hosted by Damian Garde, Rebecca Robbins, and Adam Feuerstein. This show offers a mix of current biotech news, deep dives into the industry, and upcoming events. For a first listen, try “Fake friends at the FDA, cancer counter-narratives, and biotech’s bear turn.” The Readout LOUD is available on iTunes, SoundCloud, and Stitcher.

Another biotech-focused podcast we’re enjoying is The Long Run with Luke Timmerman. Tune in to hear Luke Timmerman, author of The Timmerman Report, chat with leading figures in the biotech space, such as LaVoieHealthScience client Chris Garibidian, and Life Science VC Bruce Booth. Check out the archives here.

Sprung out of an Emmy-nominated documentary, Rare in Common serves as a platform for people impacted by rare disease to share their stories. Host Andra Stratton chats with patients, caregivers, and physicians from the rare disease community, telling stories which enable us to rethink what being rare really means. Explore the Rare in Common site to find past episodes and information about the documentary.

For your PR & Marketing needs…

The SHEQuality podcast, presented by the PR Council, is recorded weekly and hosted by Lee Caraher, a seasoned communications strategist, CEO, and author of two business leadership books.  Each week, Lee interviews senior female leaders in PR and Communications to discuss their personal stories, touching on challenges they’ve faced, landmark achievements, and their best advice for other professionals.  Keep an eye out for the episode “Woke at Work”, featuring LHS President and CEO, Donna LaVoie, for commentary on unconscious bias, decision making ,and women in STEM.

Marketing Over Coffee supplies listeners with new content weekly, as hosts John J. Wall and Christopher S. Penn record their podcast in a local coffee shop over a cup of Joe.  Episodes are only 20 minutes long and contain quality marketing tips and tricks.  Listen to “Google Marketing Platform, Quantum Computing and The Last Blockbuster!” on your next commute.

Just for fun…

Looking for something a bit lighter? Try Two Disabled Dudes, a podcast where friends Sean Baumstark and Kyle Bryant interview guests, talk about their lives, and generally have a good time. Both hosts are affected by a rare disease called Friedreich’s ataxia (FA), which impacts their balance and coordination. Their positive attitude, humor, and open perspectives make this podcast truly stand out.

Hosts Christina Wallace and Cate Scott Campbell base their podcast, The Limit Does Not Exist, on the mentality that creativity and STEM work better together.  Guests are often described as “Human Venn Diagrams” – artists, musicians, and scientists all rolled into one.  Cate and Christina recently chatted with Kevin Clark, a philanthropy consultant, product manager, and musical composer – just one of many diverse and engaging individuals who appear on the show.

LHS Partners with LSX World Congress USA

 
 
The LSX World Congress brought life science executives together here in Boston for strategy, investment, and partnering opportunities. As an event partner, LHS is thrilled to have participated in several key event tracks, including IPO Bootcamp, the Big Data Driven Innovation panel and two Fireside Chats.  
Fireside chat with Donna LaVoie and Pavan Cheruvu

As co-host of the IPO Bootcamp, held on Tuesday, October 9, at the Union Club in Boston, LHS was thrilled to be the investor relations consultant for executives looking for best practices for a successful IPO. The day began with an opening address from David Ethridge of PwC on the current state of the IPO market, and continued with an overview of the healthcare ECM from Jordan Saxe, Senior Managing Director at Nasdaq. A roundtable discussion on determining and defining an IPO strategy followed, with leaders from PwC, Nasdaq, Covington & Burling, Oppenheimer & Co, and LavoieHealthScience offering insights.

We are also grateful to have had SVP and General Manager, Doug Russell, moderate the LSX panel on Big Data Driven Innovation on Thursday, October 11.  Pharma and life science executives discussed how they’re harnessing the power of big data to advance drug discovery and development. Panelists included Leila Pirhaji, Founder and CEO of ReviveMed, Josh Mandel-Brehm, CEO of Camp4 Therapeutics, Gini Desphande, Founder and CEO of NuMedii, Alex de Winter, Managing Director at GE Ventures, and Janna Hutz, Senior Director, Head of Human Biology & Data Science at Eisai.  Doug led a lively discussion on the topic, with a focus on the future promise of big data in life science innovation.

Big Data Panel with Doug Russell
Fireside Chat with Paul Sagan and Brian Pereira

CEO Donna LaVoie and Paul Sagan, AVP, Investor Relations and Communications, also conducted fireside chats with pharma executives at the LSX World Congress.  Pavan Cheruvu, the CEO of Axovant, spoke with Donna LaVoie on the details of building a successful gene therapy portfolio.  Later in the evening, Paul Sagan and Brian Pereira, the CEO of Visterra, discussed the anatomy of a clinical-stage acquisition.  Pereira, whose company was recently acquired by the Pharmaceutical Co., Ltd of Japan, offered a timely and relevant perspective on the topic. 

The two day conference offered many interesting and engaging panels as well as great networking opportunities. LHS is happy to have partnered with LSX this year for a successful World Congress.

Communications Strategies to Prepare for an IPO, and Beyond

Communications Strategies to Prepare for an IPO, and Beyond

How you tell your company’s story before, during and after an IPO can have a big impact on your valuation and market success 

Preparing for an IPO signs you and your company up for months of hard strategizing, messaging and decision-making to effectively tap the public markets. With the complexities of changing market dynamics, mandated disclosures and Federal securities regulations, navigating the process is a challenge. And since the 2012 JOBS Act, allowing for confidential S-1 filing, many companies simply do not bother with the hard work of building their presence in the marketplace before the registration statement is publicly filed.  

 

That can be a big mistake.  Your IPO is a once-in-a-corporate lifetime chance to position your company, not only in the minds of investors, but with your customers, prospects and other key stakeholders.  

Not taking full advantage of the visibility gained during the IPO process can do a disservice to your company and your future shareholders.     

Pre-IPO: putting the communications infrastructure in place 

Before the IPO process even gets underway — to maximize your chances of success in the public markets — you’ll need to put in place a solid communications infrastructure that includes a detailed messaging strategy, a timeline of your news flow, a priority list of your key audiences.  

Targeting the right stakeholders at the right time is vitally important, especially for companies in the life science sector.  Ensuring that your customers, key opinion leaders (KOLs)/physician groups, and patient/advocacy groups understand the company story will pay dividends. Wall Street will conduct its own detailed research to find out exactly what these third parties think about your products, your company, and how they all fit into the competitive “space.” Getting your story understood and validated by KOLs and customers can have a major impact on how “the Street” eventually views and values your company.  

This is also the time to review and evaluate your press release strategy. Think about and create an inventory of “news pegs” or story ideas that could go out before your “quiet period” starts immediately before your filing. You’ll need to further craft your story through your investor materials such as fact sheets, corporate presentations, management videos, websites and external Q&A documents. 

You should also consider conducting an investor positioning session or perception audit to help refine your corporate story. This process can help you develop a peer group from which to benchmark or refine your company’s working investment thesis and set appropriate corporate milestones.  

And you’ll want to cultivate third-party spokespeople who can speak about your company to the media, begin developing your corporate investor presentation and, importantly, train your internal corporate spokespeople. Message training is like finishing a package off with a bow. Taking your presentations to 100 percent effectiveness by message training the team will prove to be worth the investment.  

The IPO Process – staying visible, keeping compliant 

The communications roadmap and regular PR activities that you put into place during the pre-IPO preparatory phase will serve you well as you enter into the regulated world of communications immediately before and after “filing” your IPO.  

Federal securities law limit the kind of information a company may use to offer stock in its IPO and the way they provide that information. These “quiet period” limitations can seem to conflict with the need for companies to continue business as usual.  After all, companies need to engage in marketing, public relations and advertising to promote themselves, reach customers and generate sales.  

But if you’ve established a “track record” of “regularly released factual business information in the ordinary course of business” during your pre-IPO phase, you can maintain communications with your clients and prospects, satisfying the “safe harbor” on communications and not be accused of “gun jumping.”     

You’ll still need to closely coordinate with your securities attorney on communications immediately before or after the registration period, as it is potentially easy to run afoul of securities regulations. But with the proper preparation in the pre-IPO stages, there should be no reason for you to go silent in your communications with customers or prospects.   

Post-IPO: keep the momentum moving 

Once you complete your IPO and begin public trading, there’s a natural tendency to take a breath and just do the mandated minimum in terms of communications. But remember, going public probably generated the most visibility and media interest your company has ever had. Now is not the time to take your foot off the accelerator.   

Your post-IPO communication strategies are crucial for managing relations with Wall Street and keeping yourself compliant with Federal regulations.  As a newly public company reporting to the Securities and Exchange Commission, you’ll need to develop internal processes to execute your earnings releases and 8-K filings, your 10-Q and 10-K submissions, develop relevant “non-GAAP” financial information and script your quarterly conference calls with investors and analysts.  

It’s definitely a lot of work, but to maximize the effort that you put into becoming a public company, it can’t end there. This is where the timeline and message strategy you created before you went public comes into play.  

Look at the initiatives you may have put on the back burner prior to the IPO. Now may be the time – with heightened attention on your company – to put them in place. Take advantage of the contacts and relationships you’ve made with the media during the IPO process to keep them informed.  And not just with disclosure communications, but with stories that show the breadth of our company. After all, your company is more than just a stock symbol and a ticker price.   

Keeping your company’s communication strategy front and center throughout the three phases of the IPO process will greatly increase your visibility and ultimately help ensure that your company achieves a full and fair valuation, once it becomes public – and beyond.  

* * * 

Donna L. LaVoie is President and Chief Executive Officer of LaVoieHealthScience.

LaVoieHealthScience to Co-Host the IPO Bootcamp at the LSX World Congress USA

Our agency is excited to be co-hosting the IPO Bootcamp at the LSX World Congress on October 9, 2018 in Boston, MA.

The IPO Bootcamp is a full day immersive workshop focused on effectively navigating the nuances of an initial public offering.  In addition to LHS, this bootcamp is co-hosted with Covington & Burling LLP, Nasdaq, and Oppenheimer & Co, Inc.  LHS will provide personalized expertise on public relations, investor relations, and corporate communications strategy to nine attending CEOs.

Executives planning to take their company public have the opportunity for 1:1 sessions with co-hosts to explore individualized mechanics, ideas, and best practices throughout the IPO process.  Discussions will be thorough and transparent, offering companies quality insights on the ins and outs of a successful IPO.

Discussions include:

  • Keynote address: the current state of capital markets
  • Anatomy of an IPO: Back to back case study discussions of IPOs
  • Legal preparations
  • Financial PR and communications
  • Regulatory requirements and IPO checklists

The IPO Bootcamp will take place one day prior to the LSX World Congress USA conference, which offers education, strategies, and solutions for life science executives to grow their business. The event will be held at the Union Club at 8 Park St, Boston, MA.

LaVoieHealthScience Promotes Sharon Correia to Senior Vice President, Integrated Communications

Boston, MA – September 5, 2018 – LaVoieHealthScience (LHS), an integrated investor and public relations agency focused on advancing health and science innovations, today announced the promotion of Sharon Correia to Senior Vice President, Integrated Communications.

Ms. Correia joined LHS in 2016 as Vice President, Integrated Communications from Navidea Biopharmaceuticals, where she was Sr. Director of Corporate Communications. An industry veteran with more than two decades of health and science communications experience spanning agency, publicly-traded and private companies, Sharon designs and executes programs that resonate from development phase through commercialization. Sharon has demonstrated alignment with LHS’s core values and a fast-moving, collaborative culture focused on problem solving.

“I am delighted to celebrate Sharon’s success at LHS and the engagement and experience that she brings to our people, clients and community. In her new role, Sharon continues to report to me and works with the senior leadership team on client strategy, execution, team building and high-level programming,” stated Donna L. LaVoie, President & CEO of LaVoieHealthScience.

Sharon brings industry-tested integrated communications experience spanning public and medical communications, investor communications and professional advocacy relations. She’s led communications teams for multiple new drug applications in the US and EU, global product launches as well as several sNDA’s, IPOs and key data dissemination at medical meetings.

“I am truly excited to continue to contribute my expertise to the well-regarded group of specialized thinkers at LHS who are solving client problems and helping them advance health and science innovation,” said Correia. “Each and every LHS client provides our team with unique and dramatic perspectives on how creative story-telling creates competitive advantage.”

About LaVoieHealthScience
LaVoieHealthScience partners with leading health and science brands to build value for their companies, attract capital and reach key stakeholders through integrated communications and marketing. The firm provides public relations, investor relations and marketing and digital communications to build recognition and increase sales and value for health science innovations. The agency has received over 30 awards over the past seven years in recognition of the work it has done for its health and science industry-leading clients and was inducted in the 2018 Inc. 5000 Hall of Fame List of Fastest Growing Private Companies. LaVoieHealthScience represents leaders such as, Emmaus Life Sciences, Landos Biopharma, LEO Science & Tech Hub, Life Sciences Corridor, NewLink Genetics, Newron Pharmaceuticals, Origenis GmbH, PathMaker Neurosystems, Scioto Biosciences, Symbiotix Biotherapies, Triumvira Immunologics, XenoTherapeutics, Xontogeny LLC, and other emerging health and science companies.

###

Media Contact:
Katie Gallagher
Account Manager, PR and Marketing
kgallagher@lavoiehealthscience.com
617-374-8800 x109

LaVoieHealthScience Enters Inc. 5000 Hall of Fame as Five-Year Honoree

Demand for Integrated Investor and Public Relations Services from Health Science Innovators Drives 73% Three-Year Growth   

 

LaVoieHealthScience has been recognized on the prestigious Inc. 5000 list for the fifth time. This puts LaVoieHealthScience in the Inc. 5000 Hall of Fame – an honor bestowed on only 10% of listed companies.  Each year, Inc. magazine recognizes the fastest-growing private companies in the U.S., showcasing the immense level of development throughout the country. The list was released on August 15, 2018 and can be viewed here: https://www.inc.com/inc5000/index.html

“We are extremely proud to have achieved a spot on the Inc. 5000 for a third year in a row and fifth year overall – and entering the Hall of Fame is icing on the cake,” said Donna LaVoie, President and CEO of LaVoieHealthScience. “Our three-year growth rate of 73% is testament to our domain expertise and track record of providing strategic, integrated communications services to health and science clients worldwide. We’ve assembled a terrific roster of clients and a seasoned team of strategic advisors – positioning us well for further growth and momentum!”

About LaVoieHealthScience

LaVoieHealthScience partners with leading health and science brands to build value for their companies, attract capital and reach key stakeholders through integrated communications and marketing. The firm provides public relations, investor relations and marketing and digital communications to build recognition and increase sales and value for health science innovations. The agency has received over 30 awards over the past seven years in recognition of the work it has done for its health and science industry-leading clients and was inducted in the 2018 Inc. 5000 Hall of Fame List of Fastest Growing Private Companies. LaVoieHealthScience represents leaders such as, Emmaus Life Sciences, Landos Biopharma, LEO Science & Tech Hub, Life Sciences Corridor, NewLink Genetics, Newron Pharmaceuticals, Origenis GmbH, PathMaker Neurosystems, Scioto Biosciences, Symbiotix Biotherapies, Triumvira Immunologics, XenoTherapeutics, Xontogeny LLC, and other emerging health and science companies.

LaVoieHealthScience Selected as a PRNews Platinum Award Finalist

Award Recognizes Excellence in Financial/Investor Relations

 

Boston, MA- August 22, 2018- LaVoieHealthScience (LHS),  an integrated investor and public relations agency focused on advancing health and science innovations, has been selected as a PRNews Platinum Award finalist in the Investor/Financial Relations Campaign category. The awards ceremony will take place on September 21st, 2018 at the Grand Hyatt in NYC. The nomination is for the agency’s work on behalf of its client Ampio Pharmaceuticals, a development stage biopharmaceutical company focused on novel therapies to treat common inflammatory conditions.

LaVoieHealthScience developed a multi-faceted financial/investor relations integrated communications plan for Ampio to optimize the impact of the release of pivotal Phase 3 data results for their leading drug candidate Ampion™, a treatment for severe osteoarthritis of the knee.

The campaign included traditional, paid and social media, and was designed to reach all stakeholders with concise and compelling messaging for a broad audience. This included patients, physicians, strategic partners and investors. The campaign also included a press release that was offered to reporters under embargo, as well as a post-distribution follow-on campaign that targeted the full range of national, local, business, trade and orthopedic outlets. The campaign included sponsored print and radio content.

“LaVoieHealthScience is thrilled to be selected as a finalist for the PRNews Platinum Awards for our client Ampio Pharmaceuticals,” said Donna L. LaVoie, President & CEO, LaVoieHealthScience. “This is a stand-out example of how to gain maximum visibility through an integrated campaign using paid, earned and social media.”

The PRNew’s Award follows LaVoieHealthScience taking home the Silver Bell Ringer Award in the Investor/Financial Relations Campaign category from the Publicity Club of New England at the 50th Annual Bell Ringer Awards in Boston. This honor was also for their work with Ampio Pharmaceuticals in the same category as their newest nomination.

About LaVoieHealthScience

LaVoieHealthScience partners with leading health and science brands to build value for their companies, attract capital and reach key stakeholders through integrated communications and marketing. The firm provides public relations, investor relations and marketing and digital communications to build recognition and increase sales and value for health science innovations. The agency has received over 30 awards over the past seven years in recognition of the work it has done for its health and science industry-leading clients and was inducted in the 2018 Inc. 5000 Hall of Fame List of Fastest Growing Private Companies. LaVoieHealthScience represents leaders such as, Emmaus Life Sciences, Landos Biopharma, LEO Science & Tech Hub, Life Sciences Corridor, NewLink Genetics, Newron Pharmaceuticals, Origenis GmbH, PathMaker Neurosystems, Scioto Biosciences, Symbiotix Biotherapies, Triumvira Immunologics, XenoTherapeutics, Xontogeny LLC, and other emerging health and science companies.

 

Contact:
LaVoieHealthScience
Katie Gallagher
Investor Relations & Corporate Communications
kgallagher@lavoiehealthscience.com

Communicating Effectively and Persuasively to Mixed Stakeholder Audiences

Communicating Effectively and Persuasively to Mixed Stakeholder Audiences

In most industries – and especially when dealing with health and science innovation – it’s critical for communicators to reach an array of stakeholders: investors, business partners, consumers, regulatory agencies, the media and advocacy groups. Whether a company is privately-held or public, building branding and messaging that resonates across all stakeholder audiences is essential.

On August 2nd, LaVoieHealthScience (LHS) explored these issues when our founder and CEO, Donna LaVoie, moderated a panel discussion at The Writing for PR and Corporate Communications Conference, presented by Ragan Communications and held at McDermott Will & Emery’s Boston office. The heavy-hitting panel included Sharon Correia, VP, Integrated Communications, LHS, Matt Osborne, VP, IR and Corporate Communications, Voyager Therapeutics, Inc., and Stella Lin, senior healthcare marketing leader, formerly with Sanofi Genzyme.  These communications experts discussed the importance of differentiating and prioritizing stakeholder audiences, balancing messaging to address individual stakeholder needs, mapping out a communications plan with aligned messages, and persuading management to think more broadly – and strategically – across the audience mix.

Key panel takeaways:

Sharon Correia explained how stakeholder prioritization and messaging alignment is core to LHS’ approach to strategic communications. Starting with a proprietary methodology called LHS Immersion®, Sharon explained how, “we work with internal and external client stakeholders to help establish the groundwork for key messages…then we take each message pillar and stratify those against the audiences they are trying to influence, creating topline and secondary messages.” The goal is to establish clear, differentiated positioning pegged to each stakeholder audience and ensure messaging alignment across all channels. Once a messaging strategy is developed, it’s pulled through to overarching themes for story development, news flow, paid, earned, shared and owned (PESO) content distribution, thought leadership and social campaigns.

Matt Osborne of Voyager Therapeutics further broke down the importance of effective, targeted communication to key stakeholders. “You could be a $500B company or a $500M market cap company….60% of your stock price is usually based on the product you have, how you’re competing in the marketplace, another 20% of stock price is due to things beyond your control, but the remainder is absolutely in the control of corporate communications or IR: It’s what you say, how you say it, and when you say it. Companies that do that really well, capture that 20% of value all the time.”

Matt believes the key to effective messaging is to “understand all the functional stakeholder groups, understand who you’re speaking to, simplify the messages and get agreement for those messages.” He went on to discuss how his communications team develops simple, concise statements that apply to all audiences and that everyone internally can agree on. “Sometimes it’s not until you boil messaging down into two or three simple statements that people all agree…and if it’s not clear internally it won’t be clear or resonate externally.”

 

On the same thread, Stella Lin emphasized how important messaging alignment is during a fire drill situation, coming down to two simple ideas: commonality and preparation. “When you’re in a crisis, trying to get the communications out, [you] have so little time to try and align…start with the commonality – we all want to do disease awareness, right? Start there, whether you’re a doctor or a patient or communications professional.” As a best practice, Stella would meet regularly with different departments and share the market research and stakeholder feedback she was receiving to make sure everyone was on the same page. Further, when Stella looked at her positioning and messaging the first step was to decide what she was trying to communicate – what type of news, is there a call to action – and who her consumers are. Scientific information and complicated concepts need to be transformed into easy-to understand messages if the audience includes more than health care professionals. In healthcare, her consumers could be essentially anyone. Patients, patient caregivers, families, patient organizations, even the general public — all need to be taken into consideration when messages are being formed. Having a team that is aligned and prepared can help make that process easier.

 

LaVoieHealthScience Adds XenoTherapeutics to Client Roster

Boston-based XenoTherapeutics Aims to Bring Life-Saving Innovation from The Lab to Address the Global Shortage of Transplantable Organs and Tissues

Boston, MA – July 20, 2018 –  LaVoieHealthScience (LHS), an integrated investor and public relations agency focused on advancing health and science innovations, today announced the addition of XenoTherapeutics to its client roster as its agency of record for strategic communications. XenoTherapeutics is partnering with LHS to build a messaging framework to educate stakeholders on the company’s proprietary platform technology to advance xenotransplantation, the science of transplanting organs and tissues of different species.

XenoTherapeutics’ mission is to provide innovative, affordable, and safe medical solutions to patients in critical need in both the U.S. and around the globe.  Its initial product candidate, Xeno-Skin, is intended to serve as a replacement or a complement to the current “gold standard” of burn treatment: human cadaver allograft. However, unlike the limited quantity of lifesaving human graft material available, Xeno-Skin is intended to be mass-produced, stored, and rapidly shipped when needed. Ultimately, the goal is to increase emergency preparedness for unexpected catastrophic events at home and fill current shortages experienced far too frequently around the world today. The XenoTherapeutics pipeline starts with skin, but envisions myriad applications of the technology, including nerves and solid organs.

“In selecting a communications partner, we did our due diligence,” said Paul Holzer, Co-founder and Chief Executive Officer of XenoTherapeutics. “LHS stood out with its deep understanding of the business and regulatory aspects of science and medicine, its team of high-touch senior leaders, and proprietary approach to creating targeted messaging mapped to stakeholders as the underpinning of a strategic communications program. We are looking forward to a long and fruitful relationship.”

Donna L. LaVoie, President & CEO of LaVoieHealthScience commented, “We are delighted to be working with the XenoTherapeutics team to bring attention to their pioneering work in seeking to address the worldwide shortage of organs for transplantation. Headed by a former U.S. Navy SEAL, XenoTherapeutics’ entrepreneurial culture, sense of purpose, and innovative technology based on rigorous scientific research has the potential to be an industry game-changer.”

About XenoTherapeutics

XenoTherapeutics’ goal is to provide safe, scalable transplantation solutions based on three decades of research by some of the world’s top leaders in xenotransplantation, surgery and infectious disease. The company’s proprietary platform leverages genetically-engineered pigs to provide a supply of temporary tissues and organs that are less susceptible to human rejection.

The company has developed a non-human organ transplant solution currently under investigational review by the FDA, which has the potential to catalyze the science of xenotransplantation and address a critically unmet need for organs and tissues across the globe. For more information, please visit: https://www.xenotherapeutics.org/